PTPI (Petros Pharmaceuticals) Current Accrued Expense: $0.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Petros Pharmaceuticals Current Accrued Expense?

Petros Pharmaceuticals PTPI +3.93% Current Accrued Expense is $0.06 Mil as of Mar. 2026.

Petros Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.06 Mil.

Petros Pharmaceuticals's quarterly Current Accrued Expense declined from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.14 Mil) and declined from Dec. 2025 ($0.14 Mil) to Mar. 2026 ($0.06 Mil).

Petros Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2023 ($4.62 Mil) to Dec. 2024 ($0.10 Mil) but then increased from Dec. 2024 ($0.10 Mil) to Dec. 2025 ($0.14 Mil).

Petros Pharmaceuticals Current Accrued Expense Related Terms

Petros Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Current Accrued Expense Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 22.89 3.05 4.62 0.10 0.14

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 0.03 0.15 0.14 0.06

Petros Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.06 Mil mean?
Petros Pharmaceuticals (PTPI) has a Current Accrued Expense of $0.06 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Petros Pharmaceuticals and its competitors.
Is Petros Pharmaceuticals' Current Accrued Expense too high?
Petros Pharmaceuticals' current Current Accrued Expense is $0.06 Mil.
How does Petros Pharmaceuticals' Current Accrued Expense compare to KOAN and KAYS?
Petros Pharmaceuticals' Current Accrued Expense of $0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current Current Accrued Expense is $0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Current Accrued Expense of $0.06 Mil. The current Current Accrued Expense is $0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Current Accrued Expense is $0.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.